2 active not recruiting, 2 not yet recruiting, 1 enrolling by invitation, 1 recruiting. 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Active not recruiting 2, Not yet recruiting 2, Enrolling by invitation 1, Recruiting 1 |
Follow Progressive Pulmonary Fibrosis: new trials by email Literature Review of Progressive Pulmonary Fibrosis trials Research Report on Progressive Pulmonary Fibrosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Progressive Pulmonary Fibrosis (PPF) Treprostinil Palmitil Inhalation Powder, Placebo - Progressive Pulmonary Fibrosis, Interstitial Lung Disease | Phase 3 | Not yet recruiting | Insmed Incorporated | 800 | 2026-12-01 | 2026-09-04 |
| Evaluating the Efficacy and Safety of of HSK44459 in People With Progressive Pulmonary Fibrosis HSK44459, Placebo - Progressive Pulmonary Fibrosis | Phase 3 | Not yet recruiting | Haisco Pharmaceutical Group Co., Ltd. | 378 | 2026-04-05 | 2026-03-31 |
| A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast Nerandomilast - Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis | Phase 3 | Active not recruiting | Boehringer Ingelheim | 1666 | 2024-09-26 | 2026-10-28 |
| Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) Placebo, Inhaled Treprostinil, Treprostinil Ultrasonic Nebulizer - Progressive Pulmonary Fibrosis, Interstitial Lung Disease | Phase 3 | Recruiting | United Therapeutics | 698 | 2023-10-30 | 2026-07-13 |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis BMS-986278, BMS-986278 Placebo - Progressive Pulmonary Fibrosis | Phase 3 | Active not recruiting | Bristol-Myers Squibb | 1057 | 2023-10-25 | 2026-04-23 |
| Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease Inhaled Treprostinil, Treprostinil Ultrasonic Nebulizer - Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease | Phase 3 | Enrolling by invitation | United Therapeutics | 1850 | 2022-09-06 | 2026-10-19 |
Lung Diseases, Interstitial (4) · Idiopathic Pulmonary Fibrosis (2) · Arthritis, Rheumatoid (1) · Connective Tissue Diseases (1) · Fibrosis (1) · Pulmonary Fibrosis (1) · Sarcoidosis (1) · Scleroderma, Diffuse (1)
Lung Diseases (5) · Respiratory Tract Diseases (5) · Pulmonary Fibrosis (2) · Arthritis (1) · Autoimmune Diseases (1) · Hemic and Lymphatic Diseases (1) · Hypersensitivity (1) · Hypersensitivity, Delayed (1) · Immune System Diseases (1) · Joint Diseases (1) · Lung Diseases, Interstitial (1) · Lymphatic Diseases (1) · Lymphoproliferative Disorders (1) · Musculoskeletal Diseases (1) · Pathologic Processes (1)
treprostinil (2) · BI 1015550 (1)
United Therapeutics (2) · Boehringer Ingelheim (1) · Bristol-Myers Squibb (1) · Haisco Pharmaceutical Group Co., Ltd. (1) · Insmed Incorporated (1)
Argentina (4) · Australia (4) · Belgium (4) · Canada (4) · Chile (4) · France (4) · Germany (4) · Israel (4) · Italy (4) · South Korea (4) · Taiwan (4) · United States (4) · Denmark (3) · Mexico (3) · Netherlands (3)
2023 (2)